| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,939 | -5,412 |
| Depreciation and amortization expense | 71 | 47 |
| Stock-based compensation expense | 1,046 | 707 |
| Change in fair value of convertible notes | -7,810 | -7,810 |
| Non-cash lease expense | 53 | 35 |
| Accretion of discounts on short-term investments | 166 | 141 |
| Interest accrued on convertible notes | 651 | 651 |
| Prepaid expenses and other assets | 1,564 | 1,717 |
| Accounts payable and accrued expenses | 919 | 132 |
| Operating lease liabilities | -75 | -49 |
| Net cash used in operating activities | -17,814 | -13,557 |
| Purchases of short-term investments | 31,486 | 31,486 |
| Maturities of short-term investments | 16,402 | 11,053 |
| Net cash used in investing activities | -15,084 | -20,433 |
| Cash acquired in connection with the merger | 24,992 | 24,992 |
| Payments for merger transaction costs | 2,821 | 2,392 |
| Proceeds from exercise of stock options | 531 | 424 |
| Net cash provided by (used in) financing activities | 22,702 | 23,024 |
| Net decrease in cash and cash equivalents | -10,196 | -10,966 |
| Cash and cash equivalents at beginning of period | 31,614 | - |
| Cash and cash equivalents at end of period | 21,418 | - |
Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (TVRD)